Denali Therapeutics Inc.
DNLI
$24.20
-$0.72-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.60M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.60M | -- | -- | -- | -- |
| Cost of Revenue | 97.11M | 103.85M | 97.91M | 101.95M | 102.70M |
| Gross Profit | -93.51M | -103.85M | -97.91M | -101.95M | -102.70M |
| SG&A Expenses | 36.28M | 33.51M | 39.46M | 35.48M | 32.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.40M | 137.36M | 137.37M | 137.43M | 134.96M |
| Operating Income | -129.79M | -137.36M | -137.37M | -137.43M | -134.96M |
| Income Before Tax | -127.55M | -128.45M | -128.45M | -126.90M | -124.12M |
| Income Tax Expenses | -- | -- | 102.00K | -- | -- |
| Earnings from Continuing Operations | -127.55M | -128.45M | -128.55M | -126.90M | -124.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.55M | -128.45M | -128.55M | -126.90M | -124.12M |
| EBIT | -129.79M | -137.36M | -137.37M | -137.43M | -134.96M |
| EBITDA | -125.31M | -133.60M | -133.58M | -133.57M | -131.01M |
| EPS Basic | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 |
| Normalized Basic EPS | -0.42 | -0.43 | -0.46 | -0.46 | -0.45 |
| EPS Diluted | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 |
| Normalized Diluted EPS | -0.42 | -0.43 | -0.46 | -0.46 | -0.45 |
| Average Basic Shares Outstanding | 187.31M | 186.64M | 175.46M | 172.42M | 171.45M |
| Average Diluted Shares Outstanding | 187.31M | 186.64M | 175.46M | 172.42M | 171.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |